Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study is a clinical trial[1].
Key Facts
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study is in the country of Phase II Study — country (P17): Switzerland[2].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's instance of is recorded as Phase II Study — instance of (P31): clinical trial[3].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's start time is recorded as +2017-01-01T00:00:00Z[4].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's end time is recorded as +2021-06-30T00:00:00Z[5].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's contributor to the creative work or subject is recorded as Phase II Study — contributor to the creative work or subject (P767): University of Zurich[6].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's main subject is recorded as Phase II Study — main subject (P921): malignant hyperthermia[7].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's main subject is recorded as Phase II Study — main subject (P921): fever[8].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's number of participants is recorded as {'unit': '1', 'amount': '+78'}[9].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's title is recorded as A Phase II Randomized Study of Concurrent Hyperthermia and Chemoradiotherapy vs. Chemoradiotherapy Alone Following Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (HEATPAC)[10].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's short name is recorded as HEATPAC[11].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[12].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's ClinicalTrials.gov ID is recorded as NCT02439593[13].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}[14].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's clinical trial phase is recorded as Phase II Study — clinical trial phase (P6099): phase II clinical trial[15].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's research site is recorded as Phase II Study — research site (P6153): Aarau cantonal Hospital[16].
- Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study's study type is recorded as Phase II Study — study type (P8363): interventional study[17].